Clicky

Swedish Orphan Biovitrum AB (publ)(SOBI) News

Date Title
Feb 20 EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN
Feb 20 Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
Oct 9 Invitation: Sobi's Q3 2024 report
Jun 19 European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A
Apr 26 Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Apr 25 Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Apr 4 Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
Jan 5 Sobi's Chairman of the Board resigns due to health reasons
Nov 30 Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)